DIREcTORs REPORT FINANcIAL REVIEW 31 profit and an 8% increase in Core earnings We recently announced an expanded per share to $5.10.
scope for our restructuring programme to drive further improvements in our Cash generation was strong in 2008: cash long-term competitiveness.
Overall, from operating activities increased by over the programme is now anticipated to $1.2 billion, driven principally by an increase deliver $2.1 billion in annual savings by in earnings before interest, tax, depreciation the end of 2010 up from $1.4 billion, and amortisation EBITDA and reduced reaching $2.5 billion per annum by 2013.
In 2008, sales increased by 3%, with working capital outflows.
This enabled us The restructuring costs to deliver these sales growth driven by our key brands, to make the payment to Merck as part of benefits are now expected to be the addition of MedImmune and the the planned phased exit arrangements, $2.9 billion up from $2 billion.
strong performance of Emerging Markets invest in capital and intangible assets businesses which grew at 16%.
Core to drive future business growth and Our continued efforts to drive efficiencies operating margin increased by productivity and fund a 10% increase in throughout the business, combined 1.6 percentage points in constant the full year dividend, whilst at the same with a strong focus on converting currency terms, as a result of improved time reducing our net debt by more than growth in EBITDA into cash, should efficiencies throughout the organisation $1.9 billion to $7.2 billion at the end of 2008. ensure resilient financial performance and delivery of our restructuring initiatives.
This strong performance puts us well ahead as we face an increasingly challenging The improved Core operating margin of our plan to reduce net debt to $7 billion external environment.
translated 3% sales growth for the year by the end of 2010. into a 9% increase in Core operating SImoN loWTh Chief Financial Officer The purpose of this Financial Review is to mEASuRINg pERFoRmANCE Constant exchange rate CER growth provide a balanced and comprehensive rates.
CER is also a non-GAAP measure.
analysis of the financial performance of the The following measures are referred to when This measure removes the effects of business during 2008, the financial position reporting on our performance both in absolute currency movements by retranslating the as at the end of the year and the main terms but more often in comparison to earlier current years performance at previous business factors and trends which could years in this section of the Directors Report: years exchange rates and adjusting affect the future financial performance of for other exchange effects, including the business.
A reconciliation to reported performance takes into account all the performance is provided on page 33.
All growth rates in this section are expressed factors including those which we cannot at constant exchange rates CER unless influence, principally currency exchange Gross margin and operating profit noted otherwise.
rates that have affected the results of margin percentages, which set out the our business as reflected in our Financial progression of key performance margins CoNTENTS Statements prepared in accordance with and demonstrate the overall quality of International Financial Reporting Standards the business.
Measuring performance 31 IFRSs as adopted by the European Union EU and as issued by the International Prescription volumes and trends for key Business background and major events affecting 2008 32 Accounting Standards Board.
products, which can represent the real business growth and the progress of Results of operations summary analysis of year to 31 December 2008 33 Core financial measure.
This is a nonindividual products better and more GAAP measure because unlike reported immediately than invoiced sales.
Financial position, including cash flow and liquidity 2008 34 performance it cannot be derived directly from the information in the Groups Net debt, representing our interest bearing Restructuring and synergy costs 36 Financial Statements.
This measure is loans and borrowings less cash and cash Capitalisation and shareholder return 37 adjusted to exclude certain significant equivalents and current investments.
Future prospects 37 items, such as charges and provisions Results of operations summary analysis related to restructuring and synergy We believe that Core financial and growth of year to 31 December 2007 38 programmes, amortisation and the measures allow us to analyse more Financial position, including cash flow impairment of the significant intangibles transparently the progress of our business.
and liquidity 2007 40 arising from corporate acquisitions and Our recent reported results have been Financial risk management 41 those related to our current and future impacted by the global restructuring and Critical accounting policies and estimates 43 exit arrangements with Merck in the synergy programmes together with impacts US, and other specified items.
See arising from corporate acquisitions.
Other accounting information 47 page 34 for a reconciliaton of Core to reported performance.
ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008 32 Accordingly, in this Financial Review, we show The adverse impact on pharmaceutical Strong performance in Emerging financial and growth measures adjusted for prices as a result of the regulatory Markets with CER sales growth the effects of these items.
For instance, although of 16% 20% reported.
for the effects of the restructuring and synergy there is no direct governmental control costs, amortisation and impairment charges on prices in the US, action from individual Continued strong performance from recorded against MedImmune and state programmes and health insurance our five key products Arimidex, Crestor, amortisation arising on the historic bodies are leading to downward pressures Nexium, Seroquel and Symbicort with arrangements with Merck.
In other parts of the sales of $17,110 million, up 9% at CER world, there are a variety of price and on prior year sales 12% reported.
CER measures allow us to focus on the volume control mechanisms and changes in sales and expenses driven by retrospective rebates based on sales Operating profit increased by 4% at CER volume, prices and cost levels relative to levels that are imposed by governments.
Core operating profit the prior period.
Sales and cost growth increased by 9% at CER.
expressed in CER allows management to The risk of generic competition following understand the true local movement in sales loss of patent exclusivity or patent expiry Earnings per share: $4.20, an increase of and costs, in order to compare recent trends or an at risk launch by a competitor, 2% at CER 12% reported.
Core earnings and relative return on investment.
CER growth with the potential adverse effects on per share were $5.10, an increase of 8% rates can be used to analyse sales in a sales volumes and prices, for example, at CER.
number of ways but, most often, we consider the launch of generic competition to both CER growth by products and groups of Ethyol and Pulmicort Respules in 2008 Net cash inflow from operating products, and by countries and regions.
CER and Toprol-XL in 2006. activities increased to $8,742 million sales growth can be further analysed into the 2007: $7,510 million.
impact of sales volumes and selling price.
The timings of new product launches, Similarly, CER cost growth helps us to focus which can be influenced by national The partial retirement of Mercks interests on the real local change in costs so that we regulators and the risk that such new in certain AstraZeneca products in the US can manage the cost base effectively.
products do not succeed as anticipated, took place on 17 March 2008 through together with the rate of sales growth and a $2.6 billion net payment to Merck.
We recognise that CER growth rates and costs following new product launches.
Core financial measures should not be used Cash distributions to shareholders in isolation and, accordingly, we also discuss Currency fluctuations.
Our functional and were $3,349 million 2007: $6,811 million comparative reported growth measures that reporting currency is the US dollar, but through dividend payments of $2,739 reflect all the factors that affect our business.
we have substantial exposures to other million 2007: $2,641 million and share currencies, in particular the euro, Japanese re-purchases of $610 million BuSINESS BACKgRouNd ANd yen, sterling and Swedish krona.
mAJoR EVENTS AFFECTINg 2008 Macro factors such as greater demand Net debt decreased to $7,174 million The business background is covered in from an ageing population and increasing 2007: $9,112 million, a reduction of the Business Environment section of this requirements of servicing Emerging Markets.
Directors Report and describes in detail the developments in both our products Over the longer term, the success of our R&D Total restructuring and synergy costs and geographical regions.
is crucial, and we devote substantial resources associated with the global programme to this area.
The benefits of this investment to reshape the cost base of the business, Our operations are focused on prescription emerge over the long term and there is were $881 million in 2008 2007: pharmaceuticals, and over 97% of our considerable inherent uncertainty as to whether $966 million.
This brings the total costs sales are made in that sector.
Sales of and when it will generate future products.
incurred to date to $1,847 million.
pharmaceutical products are directly influenced by medical needs and are generally The most significant features of our financial paid for by health insurance schemes or results in 2008 are: national healthcare budgets.
Our operating results can be affected by a number of Reported sales of $31,601 million, factors other than the delivery of operating representing CER sales growth of 3% plans and normal competition: 7% reported.
ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008 DIREcTORs REPORT 33 RESulTS oF opERATIoNS SummARY points and intangible asset impairments and Impairment charges relating to intangible ANAlYSIS oF YEAR To 31 dECEmBER 2008 other provisions 0.8 percentage points.
fixed assets totalled $631 million during the year.
Charges totalling $407 million, including The tables on this page and the following Core R&D costs of $4,953 million were down impairments in respect of Ethyol and HPV page show our sales analysed by therapy 1% at CER over last year Reported: 0%.
vaccines, have been excluded from Core area, operating profit for 2008 compared The inclusion of a full year of MedImmune operating profit.
Charges totalling $224 million, to 2007 and a reconciliation of reported expense was offset by improved productivity including $115 million in respect of Pulmicort operating profit to Core operating profit and efficiency, restructuring benefits, portfolio Respules, have been included in Core for 2008 and 2007. changes and lower charges relating to operating profit.
Full details are provided intangible asset impairments charged to on page 35.
Sales increased by 7% on a reported basis and Core R&D expense.
Currency benefited Core operating profit was up 9% at CER reported sales by 4%.
More details on our Core SG&A costs of $9,940 million were up from 2007 Reported: up 13%.
CER Core sales performance by therapy area are given 3% at CER Reported: up 4% due chiefly operating margin increased by 1.6 percentage on pages 53 to 70, in the sections titled to the inclusion of a full year of MedImmune points to 34.7% of sales as improvements Performance 2008. costs, increased investment in our Emerging in gross margin were offset by higher SG&A Markets and some higher legal expenses.
Reported operating profits, at 28.9%, Core gross margin of 80.4% in the year was increased by 1.5 percentage points as a result 0.8 percentage points higher than last year Core other income of $734 million was of improvements in gross margin and R&D at CER Reported: 79.1%: 0.8 percentage $6 million higher than last year Reported: efficiencies which more than offset a modest points higher.
Principal drivers were lower decreased $204 million with MedImmunes increase in SG&A costs.
payments to Merck 1.0 percentage points, licensing and royalty income streams offset continued efficiency gains and mix factors by expected lower one-time gains and Net finance expense was $463 million 1.2 percentage points, partially offset by royalty income.
compared to $111 million for 2007. higher royalty payments 0.6 percentage SAlES BY ThERApY AREA 2008 ANd 2007 2008 2007 2008 compared to 2007 CER Growth due to CER Reported Reported growth exchange effect Reported growth growth $m $m $m $m % % Cardiovascular 6,963 29 248 6,686 4 Gastrointestinal 6,344 275 176 6,443 4 2 1 Infection and other 2,451 706 31 1,714 41 43 Neuroscience 5,837 346 151 5,340 6 9 Oncology 4,954 109 244 4,819 2 3 Respiratory and Inflammation 4,128 278 139 3,711 7 11 Other businesses 924 54 24 846 6 9 Total 31,601 1,029 1,013 29,559 3 7 1 Includes Synagis and FluMist which were acquired in June 2007. opERATINg pRoFIT 2008 ANd 2007 2008 2007 Percentage of sales 2008 compared to 2007 CER Growth due to Reported Reported CER Reported Reported growth exchange effect Reported 2008 2007 growth growth $m $m $m $m % % % % Sales 31,601 1,029 1,013 29,559 3 7 Cost of sales 6,598 38 217 6,419 20.9 21.7 1 3 Gross profit 25,003 1,067 796 23,140 79.1 78.3 5 8 Distribution costs 291 39 4 248 0.9 0.8 16 17 Research and development 5,179 88 71 5,162 16.4 17.5 2 Selling, general and administrative costs 10,913 433 116 10,364 34.6 35.1 4 5 Other operating income and expense 524 188 16 728 1.7 2.5 26 28 Operating profit 9,144 319 731 8,094 28.9 27.4 4 13 Net finance expense 463 111 Profit before tax 8,681 7,983 Taxation 2,551 2,356 Profit for the period 6,130 5,627 Earnings per share 4.20 3.74 Growth rates on line items below operating profit, where meaningful, are given elsewhere in this Report.
ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008 34 The increase in interest expense was driven The effective tax rate was 29.4% 2007: 29.5%.
FINANCIAl poSITIoN, INCludINg by additional borrowings arising as a result CASh FloW ANd lIQuIdITY 2008 of the acquisition of MedImmune in 2007.
Core earnings per share were $5.10, an Our exposure to interest costs was reduced increase of 8% at CER on 2007, as All data in this section is on a reported basis in 2008, from the closing position in 2007, as the increase in Core operating profit and unless noted otherwise.
we moved debt used to finance the purchase the benefit of a lower number of shares of MedImmune from short-term, higher interest outstanding was partially offset by increased Total net assets increased by $1,145 million rate commercial paper, to longer-term debt net finance expense.
Reported earnings per to $16,060 million.
The increase due to financing at lower interest rates.
Group profit of $6,101 million was offset by net finance expense benefited from a net dividends of $2,767 million and net share fair value gain of $130 million relating to gEogRAphICAl ANAlYSIS re-purchases of $451 million.
Exchange two long-term bonds due to widening credit We discuss the geographical performances movements arising on consolidation and spreads.
We anticipate that the fair value gain in the Geographic Review on pages 48 to 52. actuarial losses also reduced net assets will largely reverse as credit markets stabilise.
RECoNCIlIATIoN oF REpoRTEd RESulTS To CoRE RESulTS Restructuring and synergy MedImmune Ethyol and Merck 2008 1 Reported costs amortisation other impairments amortisation Core 2008 $m $m $m $m $m $m Gross profit 25,003 405 25,408 Distribution costs 291 291 Research and development 5,179 166 60 4,953 Selling, general and administrative costs 10,913 310 307 257 99 9,940 Other operating income and expense 524 120 90 734 Operating profit 9,144 881 427 407 99 10,958 Net finance expense 463 463 Profit before tax 8,681 881 427 407 99 10,495 Taxation 2,551 259 125 121 3,056 Profit for the period 6,130 622 302 286 99 7,439 Earnings per share 4.20 0.43 0.21 0.19 0.07 5.10 Restructuring and synergy MedImmune Ethyol and Merck 2007 Reported costs amortisation other impairments amortisation Core 2007 $m $m $m $m $m $m Gross profit 23,140 415 23,555 Distribution costs 248 248 Research and development 5,162 73 5,089 Selling, general and administrative costs 10,364 478 255 96 9,535 Other operating income and expense 728 728 Operating profit 8,094 966 255 96 9,411 Net finance expense 111 111 Profit before tax 7,983 966 255 96 9,300 Taxation 2,356 285 75 2,716 Profit for the period 5,627 681 180 96 6,584 Earnings per share 3.74 0.46 0.12 0.06 4.38 2008 2007 2008 compared to 2007 CER Growth due to CER Total core Core growth exchange effect Core growth growth 2007 to 2008 $m $m $m $m % % Gross profit 25,408 1,057 796 23,555 5 8 Distribution costs 291 39 4 248 16 17 Research and development 4,953 71 65 5,089 1 3 Selling, general and administrative costs 9,940 289 116 9,535 3 4 Other operating income and expense 734 23 17 728 3 1 Operating profit 10,958 823 724 9,411 9 16 Net finance expense 463 111 Profit before tax 10,495 9,300 Taxation 3,056 2,716 Profit for the period 7,439 6,584 Earnings per share 5.10 4.38 1 Includes $150 million of impairments against intangible assets, acquired with MedImmune, relating to the return of rights to the heat shock protein 90 Hsp90 drug candidates IPI-504 MEDI-561 and the IPI-493 to Infinity Pharmaceuticals and revised forecasts for future royalties related to HPV vaccines.
Also included is a $257 million impairment charge for Ethyol following the at risk launch of a generic competitor.
ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008 DIREcTORs REPORT 35 into the US market.
The settlement of the in three countries.
The following table shows On 17 March, AstraZeneca paid $2.6 billion to Merck.
This payment resulted in AstraZeneca Pulmicort Respules patent litigation triggered the dollar effect of a 1% change in the discount acquiring Mercks interests in certain an impairment of $115 million.
The remaining rate on the obligations in those countries.
AstraZeneca products including Pulmicort, impairments arise as a result of the termination -1% 1% of projects in development and a charge for Rhinocort, Symbicort and Toprol-XL and UK $m 739 640 has been included in intangible assets as $91 million relating to the reassessment of the US $m 226 199 explained below.
licensing income expected to be generated Sweden $m 333 263 by the HPV cervical cancer vaccine.
Reported performance includes impairments pRopERTY, plANT ANd EQuIpmENT Property, plant and equipment fell by in respect of Ethyol, HPV and other projects in $1,255 million to $7,043 million primarily development principally the return of rights to CommITmENTS ANd CoNTINgENT lIABIlITIES due to depreciation and impairments of Infinity Pharmaceuticals which management Contingent liabilities principally relate to believe are not part of Core performance.
litigation including litigation relating to $1,182 million and exchange movements of $1,131 million offset by additions of As a result, management has adjusted for employment, product liability, commercial $1,113 million.
impairments totalling $407 million in disputes, infringement of intellectual property presenting Core performance.
rights, the validity of certain patents, anti-trust, securities laws and governmental investigations.
goodWIll ANd INTANgIBlE ASSETS Goodwill and intangibles have increased INVENToRIES by $846 million to $22,197 million.
Inventories have decreased by $483 million Most of the claims involve highly complex to $1,636 million due to exchange movements issues.
Often, these issues are subject to of $298 million along with an underlying substantial uncertainties and therefore the The main components within goodwill are the amounts capitalised on acquisition of reduction in inventory of $185 million.
probability of a loss, if any, being sustained MedImmune of $8,757 million and on the and an estimate of the amount of any loss restructuring of our US joint venture with RECEIVABlES, pAYABlES ANd pRoVISIoNS are difficult to ascertain.
Consequently, for a Trade and other receivables increased by majority of these claims, it is not possible to Merck in 1998.
No significant amounts have been capitalised within goodwill in 2008.
Exchange make a reasonable estimate of the expected The total goodwill balance has reduced by rate movements reduced receivables by financial effect, if any, that will result from $10 million due to exchange rate movements.
The underlying increase of ultimate resolution of the proceedings.
In these $1,022 million was driven by increased sales cases, AstraZeneca discloses information with Intangible assets have increased by in our Emerging Markets, the extension of respect to the nature and facts of the case.
Additions major credit terms in the UK and increased totalled $2,941 million, amortisation was insurance recoverables.
Although there can be no assurance regarding the outcome of any of the legal $807 million and impairments totalled $631 million.
Exchange reduced intangibles Trade and other payables increased by proceedings, based on managements current by $603 million.
$130 million, or $675 million after removing and considered view of each situation, we do the impacts of exchange rate movements, not currently expect them to have a materially adverse effect on our financial position.
This Additions to intangible assets in 2008 included primarily due to increases in US managed a payment made to Merck under pre-existing market accruals.
Trade payables include position could of course change over time.
arrangements under which Mercks interests $2,136 million in respect of accruals relating in our products in the US will be terminated to rebates and reductions in our US market.
Assessments as to whether or not to recognise provisions or assets and of the amounts subject to the exercise of certain options.
These are explained and reconciled fully $994 million of this payment relates to certain on pages 43 and 44. concerned usually involve a series of complex specific AstraZeneca products, including judgements about future events and can rely Pulmicort, Rhinocort, Symbicort and Provisions increased by $122 million driven heavily on estimates and assumptions.
AstraZeneca believes that the provisions Toprol-XL.
As a result of the payment mainly by increases in specific insurance AstraZeneca no longer has to pay contingent and long-term provisions.
recorded are adequate based on currently payments on these products to Merck and available information and that the insurance has obtained the ability to fully exploit TAx pAYABlE ANd RECEIVABlE recoveries recorded will be received.
these products and to fully exploit other Net income tax payable has increased by opportunities in the Respiratory therapy area $667 million to $1,968 million principally due However, given the inherent uncertainties that AstraZeneca was previously prevented to tax audit provisions and cash tax timing involved in assessing the outcomes of these from doing by Mercks interests in these differences.
Net deferred tax liabilities have cases and in estimating the amount of the potential losses and the associated insurance products.
The remainder of the payment decreased mainly as a result of the impact $1,656 million represents payments of actuarial losses suffered in the year, the recoveries, we could in future periods incur on account for the product rights that will amortisation and impairment of MedImmune judgements or insurance settlements that crystallise if we exercise options in 2010. intangibles and exchange benefits.
could have a material adverse effect on our results in any particular period.
Further details of this are included in Note 25 to the Financial Statements.
RETIREmENT BENEFIT oBlIgATIoNS Net retirement benefit obligations increased by Details of the more significant matters are set In March, a $257 million intangible asset $734 million principally as a result of actuarial out in Note 25 to the Financial Statements.
impairment charge was taken as a result losses of $1,232 million offset by exchange of the entry of generic Ethyol, a product benefits of $434 million.
Approximately 95% capitalised on the acquisition of MedImmune, of the Groups obligations are concentrated ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008 36 NET dEBT When fully implemented, these and other new business reshaping activities, combined 2008 2007 $m $m with revised estimates for the original 2007 Cash and short-term investments 6,044 7,760 programme, will result in the overall programme delivering a reduction of approximately Loans and borrowings 15,156 1,223 Net debt funds brought forward at 1 January 9,112 6,537 15,000 positions by 2013.
Reductions in Earnings before interest, tax, depreciation, amortisation and impairment 11,764 9,950 positions are subject to consultations with Movement in working capital 210 443 works councils, trade unions and other employee representatives and in accordance Tax paid 2,209 2,563 Interest paid 690 335 with local labour laws.
Other non-cash movements 87 901 Net cash available from operating activities 8,742 7,510 As a result of the expanded scope of these business reshaping programmes, total Purchase of intangibles 2,944 549 Other capital expenditure net 1,057 1,076 programme charges for restructuring and Acquisitions 14,891 synergies are now estimated to reach Investments 4,001 16,516 $2,950 million.
When fully implemented, programme benefits are now estimated to Dividends 2,739 2,641 Net share re-purchases 451 3,952 reach $2.5 billion per annum.
Distributions 3,190 6,593 Other movements 387 50 Net debt carried forward at 31 December 7,174 9,112 Comprised of: Cash and short-term investments 4,674 6,044 Loans and borrowings 11,848 15,156 CASh FloW which we currently anticipate repaying from Cash generated from operating activities current cash balances of $4,286 million was $8,742 million in the year, compared and business cash flows, without the need with $7,510 million in 2007.
The increase of to re-finance.
$1,232 million was principally driven by an increase in operating profit before depreciation, Net debt of $7,174 million has decreased amortisation and impairment costs of by $1,938 million from 31 December 2007.
$1,814 million, a decrease in tax payments of $354 million and lower working capital We continue to believe that, although our outflows of $233 million, offset by an increase future operating cash flows are subject to in interest payments of $355 million and a a number of uncertainties, as specified in the decrease in non-cash items of $814 million Business Background section on page 32, our which includes movements on provisions.
cash and funding resources will be sufficient to meet our forecasting requirements, including Net cash outflows from investing activities developing and launching new products, were $3,896 million in the year compared externalisation, our ongoing capital programme, with $14,887 million in 2007. our restructuring programme, debt servicing and repayment and shareholder distributions.
Cash distributions to shareholders were $3,349 million through dividend payments RESTRuCTuRINg ANd SYNERgY CoSTS of $2,739 million and share re-purchases of $610 million.
In 2008 we continued the global restructuring and synergy programmes announced in 2007.
During the year we issued a further 500 Costs for the full year totalled $881 million of million, 5.625% 18-month bond as part of which $219 million are non-cash items.
our re-financing programme, the proceeds of which have been used to re-finance maturing This annual total reflects an extension in commercial paper.
the scope of the previously announced $1,975 million programme.
New initiatives Gross debt including loans, short-term include further rationalisation of the global borrowings and overdrafts was $11,848 supply chain, additional restructuring of the million as at 31 December 2008 2007: sales and marketing organisation and $15,156 million.
Of this debt, $993 million business infrastructure.
is due within one year 2007: $4,280 million ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008 DIREcTORs REPORT 37 CApITAlISATIoN ANd ShAREholdER RETuRN dIVIdENd FoR 2008 $ Pence SEK Payment date All data in this section is on a reported basis.
First interim dividend 0.55 27.8 3.34 15 September 2008 Second interim dividend 1.50 104.8 12.02 16 March 2009 CApITAlISATIoN Total 2.05 132.6 15.36 The total number of shares in issue at 31 December 2008 was 1,447 million.
4.1 million shares were issued in consideration of share option plans and employee share SummARY oF ShAREholdER dISTRIBuTIoNS plans for a total of $159 million.
Reserves Total Total were reduced by $2,277 million in 2008 due Shares Dividend dividend shareholder re-purchased Cost per share cost distributions to the effect of exchange rates and actuarial million $m $ $m $m losses.
This represented 0.9% of the share capital at the start of the year.
All shares re-purchased have been cancelled.
FuTuRE pRoSpECTS This brings the total number of shares re-purchased to date since the beginning The Company has set its financial targets of the re-purchase schemes in 1999, to for 2009 in anticipation of the normal range 376.3 million shares at a total cost of of risks and opportunities typical for the $18,099 million.
The Board has decided pharmaceutical sector together with the that no share re-purchases will take place turmoil in the financial markets and the in 2009 in order to maintain the flexibility broader economy.
Management believes to invest in the business.
that successful execution of its business plan, underpinned by the underlying financial In the year, 4.1 million shares were issued in and operating strength of the Company, will consideration of share option exercises for result in achievement of a resilient financial a total of $159 million.
performance even in this challenging business climate.
The Board regularly reviews its shareholder returns strategy, and in 2008 reaffirmed the dividend policy, which is to grow dividends in line with reported earnings before restructuring and synergy costs, with an aim to maintain at least two times dividend cover.
ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008 38 RESulTS oF opERATIoNS SummARY costs.
Earnings per share for 2007 were gEogRAphICAl ANAlYSIS ANAlYSIS oF YEAR To 31 dECEmBER 2007 $3.74, a 3% decline from $3.86 in 2006.
2007 sales by major region are included in the performance table on page 49 of the Core measures, as used in our commentary pERFoRmANCE CER gRoWTh RATES Geographical Review.
above on the financial results for 2008 Sales including comparison to 2007, are not Sales for 2007 increased 7%.
The contribution Sales in the US were $13,366 million in 2007 referred to in the analysis of operating margin to sales growth in 2007 from the acquisition up 7%.
In the US, sales of Nexium, Seroquel, and profit for 2007 detailed below as this of MedImmune more than offset the decline Crestor and Arimidex were $8,364 million, measure was introduced for 2008.
Where from Toprol-XL in the US.
2007 sales in the almost 63% of total US sales.
Symbicort appropriate, when comparing 2007 reported US were up 7%, and this was broadly similar was launched in the US in the year with performance to 2006, the impact of the to sales growth in the market if Toprol-XL and sales of $50 million.
Sales in Canada were acquisition of MedImmune in 2007 the impact of MedImmune were excluded.
is analysed to provide a more appropriate Sales outside the US were up 8%, comprising comparison between the two years.
growth of 5% in Established Markets and Sales in the rest of the world were $15,048 17% in the Emerging Markets.
Key products The tables below show our sales by therapy Crestor, Symbicort, Seroquel and Arimidex area and operating profit for 2007 compared For the second year, our portfolio in 2007 were up 20%.
Latin America, Middle East to 2006. had 11 brands with annual sales greater and Africa, and Asia Pacific were up 18%.
The combined sales of our Spain and the UK had sales growths of 7% REpoRTEd pERFoRmANCE key products Arimidex, Crestor, Nexium, and 8% respectively.
Sales in Germany Our 2007 sales increased by 12% from Seroquel and Symbicort grew by 11% in continued to be impacted by doctors being $26,475 million to $29,559 million, an increase 2007 to $15,344 million, and accounted for encouraged to prescribe generics in 2006 reflecting both the acquisition of MedImmune about 52% of our turnover.
Sales growth of 11% and the entry of generic competition on all was achieved in Japan in 2007. strengths of Toprol-XL in the US, as well as Details on our 2007 sales performance by general business performance.
Operating therapy area are given on pages 53 to 70, profit for 2007 fell by 1%, again reflecting in the section for each individual therapy area the impacts of MedImmune and Toprol-XL titled Performance 2007. together with restructuring and synergy SAlES BY ThERApY AREA 2007 ANd 2006 2007 2006 2007 compared to 2006 CER Growth due to CER Reported Reported growth exchange effects Reported growth growth $m $m $m $m % % Cardiovascular 6,686 292 276 6,118 5 9 Gastrointestinal 6,443 379 191 6,631 6 3 Infection and other 1,714 779 60 875 89 96 Neuroscience 5,340 484 152 4,704 10 14 Oncology 4,819 359 198 4,262 8 13 Respiratory and Inflammation 3,711 369 191 3,151 12 18 Others 846 79 33 734 11 15 Total 29,559 1,983 1,101 26,475 7 12 opERATINg pRoFIT 2007 ANd 2006 2007 2006 Percentage of sales 2007 compared to 2006 CER Growth due to CER Reported Reported growth exchange effects Reported 2007 2006 growth growth $m $m $m $m % % % % Sales 29,559 1,983 1,101 26,475 7 12 Cost of sales 6,419 703 157 5,559 21.7 21.0 13 15 Gross margin 23,140 1,280 944 20,916 78.3 79.0 6 11 Distribution costs 248 7 15 226 0.8 0.9 3 10 Research and development 5,162 944 316 3,902 17.5 14.7 24 32 Selling, general and administrative costs 10,364 843 425 9,096 35.1 34.4 9 14 Other operating income and expense 728 188 16 524 2.5 2.0 36 39 Operating profit 8,094 326 204 8,216 27.4 31.0 4 1 ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008 DIREcTORs REPORT 39 opERATINg mARgIN ANd RETAINEd pRoFIT other income of $169 million primarily through Operating profit for 2007 was $8,094 million, human papilloma virus vaccine royalty income, down 4% at CER.
Excluding restructuring other income of $559 million was $35 million and synergy costs of $966 million, 2007 higher than 2006, as expected reductions in operating profit increased to $9,060 million royalty income were more than offset by higher up 8% on 2006 at CER.
This operating one-time gains and insurance recoveries.
profit improvement was net of a reported $1,187 million increase in R&D investment, Total charges of $966 million were taken and was fuelled by revenue growth, improved in respect of the restructuring and synergy gross margin and lower expenditures in programmes in 2007, of which $723 million SG&A on a constant currency basis.
Over the same period, Restructuring and synergy benefits of productivity initiative benefits of $250 million $300 million were realised during 2007. and synergy benefits of $50 million have Reported operating margin was 27.4%.
In 2007 reported gross margin decreased by MedImmune contributed an operating loss 0.7 percentage points.
After adjusting for the of $178 million which included amortisation impact on gross margin of the acquisition of costs of $255 million in 2007.
MedImmune $472 million and restructuring and synergy costs $415 million, 2007 gross Net finance expense in 2007 was $111 million margin increased by 1.0 percentage points in the full year 2006 income: $327 million.
Principal drivers The reduction from 2006 was principally included reduced payments to Merck attributable to the interest payable on the 0.7 percentage points, asset provisions borrowings to acquire MedImmune, Inc. Interest expense on the new debt was booked during the prior period 0.4 percentage points and favourable currency movements $446 million.
The 2007 reported amounts 0.2 percentage points.
An adverse effect include net income of $34 million 2006: arose from increased royalty payments, which $43 million arising from employee benefit fund assets and liabilities reported under led to a 0.4 percentage point reduction.
R&D investment increased by 24% CER growth to $5,162 million in 2007, 17.5% The effective tax rate for 2007 was 29.5%, similar to the 29% for 2006.
The slight increase of sales, an increase of 2.8 percentage points.
After adjusting for the impact of the for 2007 compared to 2006 reflected the acquisition of MedImmune $255 million and combined effect of differences in the restructuring and synergy costs $73 million, geographical mix of profits, the reversal of tax deductions relating to share-based R&D expenditure was $4,834 million in 2007, up 16% CER growth and 2.1 percentage payments, the reduction in the UK tax rate points over 2006 due principally to as applied to UK net deferred tax liabilities, increased activity levels and the effect of and an increase in tax provisions principally in relation to global transfer pricing.
Selling, general and administrative costs Reported earnings per share for 2007 in 2007 increased by 9% CER growth to were $3.74 compared with $3.86 in 2006, a decrease of 5%.
After adjusting for the $10,364 million.
After adjusting for the impact of the MedImmune acquisition $560 million impact of restructuring and synergy costs, and restructuring and synergy costs $478 2007 earnings per share rose from $3.86 million and currency impacts, SG&A costs to $4.20, an increase of 7%.
Excluding the impact of MedImmune as well, earnings per were 2% lower than the same period in 2006, primarily as a result of operational efficiencies share increased by 15% to $4.52.
The share from our selling and marketing activities.
re-purchase programme is calculated to have added 8 cents to EPS during 2007, after allowing for an estimate of interest At $728 million, other operating income and expense in 2007 was 36% higher than 2006. income foregone.
After adjusting for the impact of the MedImmune acquisition which contributed ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008 40 FINANCIAl poSITIoN, INCludINg with Merck and the subsequent merger of SEpTEmBER 2007 CASh FloW ANd lIQuIdITY 2007 Astra and Zeneca in 1999 $1,026 million, Floating rate 2009 $650m the acquisition of Cambridge Antibody Fixed 5.4% 2012 $1,750m All data in this section is on an actual basis Technology in 2006 $605 million, launched Fixed 5.9% 2017 $1,750m unless noted otherwise.
and in development product in-licensing Fixed 6.45% 2037 $2,750m activities $1,327 million and software Fixed 5.125% 2015 750m The book value of our net assets decreased development costs $434 million.
by $501 million to $14,915 million at the NoVEmBER 2007 2007 year end.
Dividends of $2,658 million INVENToRIES and share re-purchases of $4,170 million Inventories have decreased by $131 million Fixed 4.625% 2010 750m exceeded net profit of $5,595 million, whilst from $2,250 million at the end of 2006 to Fixed 5.75% 2031 350m net movements through other recognised $2,119 million.
This decrease represents income and expense principally exchange an underlying improvement of $442 million, and actuarial losses increased net assets.
offset by the acquisition of MedImmune and $750 million each of the 2012 and 2017 US The overall shape of the balance sheet was exchange effects.
dollar fixed rate debt was swapped into changed by the acquisition of MedImmune.
As at 31 December 2007, RECEIVABlES, pAYABlES ANd pRoVISIoNS we also had commercial paper outstanding pRopERTY, plANT ANd EQuIpmENT Receivables have risen from $5,561 million amounting to $4,112 million.
Property, plant and equipment rose from to $6,668 million as at 31 December 2007, $7,453 million to $8,298 million at the end an increase of $1,107 million.
Higher sales in TAx pAYABlE ANd RECEIVABlE of 2007.
The increase was due to continued 2007, particularly in the US, Europe, China Net income tax payables increased in 2007 investment across the business of $1,169 and from the impact of the MedImmune due to tax audit provisions, less the settlement million, particularly in R&D, the acquisition acquisition whose sales are concentrated of tax on the disposal of the Humira royalty of MedImmune $593 million and exchange in the first and last quarters of the year, stream.
Net deferred tax liabilities increased impacts $350 million, offset by depreciation insurance recoveries, acquisition and primarily due to the acquisition of MedImmune and impairment of $1,182 million and exchange effects were the principal drivers, and the recognition of deferred tax liabilities in disposals $92 million.
offset in part by the receipt of the second respect of intangible assets.
instalment in respect of the US anaesthetics goodWIll ANd INTANgIBlE ASSETS business disposal in 2006.
CASh FloW Goodwill and intangibles rose from We continued to be a highly cash-generative $4,204 million at the beginning of 2007 Current payables also rose from $6,295 million business.
However, the cost of acquisition of to $21,351 million at 31 December 2007. to $6,968 million at the end of 2007.
There MedImmune meant that our funds and debt The increase is due almost entirely to the was a small net underlying movement in profile changed in 2007. acquisition of MedImmune.
The goodwill trade creditors, other payables and accruals, arising on the acquisition of MedImmune with increases in deductions for chargebacks, Cash generated from operating activities was amounted to $8,757 million increasing the rebates and returns in the US being offset $7,510 million in 2007, only slightly down on balance sheet total to $9,884 million: the by decreases in trade payables, particularly 2006 $7,693 million.
The small decrease other major component of the carrying value to Merck.
However, exchange and the in operating profit was compensated for by of goodwill relates to the restructuring in 1998 acquisition of MedImmune drove the overall an increase in non-cash items $638 million of our joint venture arrangements with Merck.
principally from unspent restructuring costs and depreciation, amortisation and Intangibles also increased in 2007, primarily Provisions increased primarily as a result of impairment $511 million.
These compensating as a result of the MedImmune acquisition, the restructuring and synergy programmes effects were offset by an increase in working supplemented by other company acquisitions undertaken during 2007, rising from $366 capital requirements of $551 million and and ongoing in-licensing activities.
Intangibles additional tax and interest payments million in 2006 to $1,020 million at the end arising from the MedImmune acquisition of 2007.
comprised launched products of $7,478 million principally the respiratory syncytial dEBT Net cash outflows from investing activities virus RSV franchise, other products such as were $14,887 million in 2007 compared to The acquisition of MedImmune was funded FluMist and Ethyol, together with contractual initially through drawing on a $15 billion 364 $272 million in 2006.
Excluding the higher and licensing income and in development day loan facility, which was subsequently returns from movements in short term projects amounting to $597 million.
In total, re-financed with short-term US commercial investments and fixed deposits and net intangibles amount to $11,467 million at the disposals of non-current asset investments paper.
In the second half of 2007, we 2007 year end and, in addition to those arising undertook a programme of issuing debt on $1,280 million in 2007 compared to from the MedImmune acquisition, include the US and European markets, as follows: $1,171 million in 2006, interest received and intangibles arising from the restructuring in dividends paid by subsidiaries, cash outflow 1998 of our joint venture arrangements from investing activities was $16,516 million in 2007, compared to $1,791 million in 2006.
This increase in outflow was due primarily to the acquisition of MedImmune, Inc. : other acquisitions included Arrow Therapeutics Limited, Atlantis Components Inc. and ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008 DIREcTORs REPORT 41 Denics International Co. Ltd. Investment in Verus Pharmaceuticals, Inc. which includes FINANCIAl RISK mANAgEmENT intangible assets was at broadly similar levels the North American rights to Captisolenabled to 2006, and there were significantly higher budesonide solution and a proprietary FINANCIAl RISK mANAgEmENT polICIES payments for property, plant and equipment albuterol formulation.
Insurance through increased investment in facilities, Our risk management processes are described particularly in research and development.
In the area of product acquisitions in 2007, in the Risk section on pages 74 to 82.
These we capitalised $100 million in respect of the processes enable us to identify risks that Cash returns in 2007 to shareholders were collaboration disclosed with Bristol-Myers can be partly or entirely mitigated through $6,811 million through share re-purchases Squibb BMS in respect of saxagliptin and use of insurance.
We negotiate best available of $4,170 million and dividend payments of dapagliflozin.
A global licensing and research premium rates with insurance providers on $2,641 million, compared to $6,367 million collaboration with Palatin Technologies Inc. the basis of our extensive risk management in 2006.
After taking into account proceeds to discover, develop and commercialise small procedures.
In the current insurance market, from the issue of share capital of $218 million molecule compounds that target melanocortin the level of cover is decreasing whilst premium 2006: $985 million, net share re-purchases receptors for the treatment of obesity and rates are increasing.
Rather than simply paying rose from $3,162 million to $3,952 million related indications was entered into, with higher premiums for lower cover, we focus in 2007. a $10 million capitalised upfront payment.
our insurance resources on the most critical We have also entered a three-year research areas, or where there is a legal requirement, Net funds of $6,537 million at the beginning and development collaboration with Silence and where we can get best value for money.
of 2007 had become net debt of $9,112 Therapeutics plc to discover and develop Risks to which we pay particular attention million by the end of 2007. proprietary siRNA molecules primarily in the include business interruption, Directors and respiratory field but with the option to extend Officers liability and property damage.
INVESTmENTS, dIVESTmENTS ANd into other disease areas.
The initial access fee CApITAl ExpENdITuRE of $5 million was capitalised as an intangible Taxation The major investment in 2007 was the asset and the $10 million equity investment was Tax risk management forms an integrated part capitalised as a non-current asset investment.
of the Group risk management processes.
Our tax strategy is to manage tax risks On the acquisition of MedImmune, the In respect of ongoing collaborations, we have and tax costs in a manner consistent with purchase price for outstanding shares made further milestone payments of $20 million shareholders best long-term interests, taking in 2007 in relation to the agreement with into account both economic and reputational of $13.9 billion was allocated between intangible assets of $8.1 billion including Protherics upon the successful scale-up factors.
We draw a distinction between assets in respect of Synagis and motavizumab of the manufacturing process under the tax planning using artificial structures and RSV franchise, FluMist, Ethyol and products development and commercialisation optimising tax treatment of business agreement and $30 million under the transactions, and we only engage in the latter.
in development, goodwill of $8.8 billion and net liabilities of $3.0 billion.
This allocation, agreement with POZEN in relation to the based on strict accounting requirements, execution of the revised agreement and Treasury does not allow for the separate recognition recognition of successful proof of concept.
The principal financial risks to which the Group We have also paid $48 million for the last in is exposed are those of liquidity, interest rate, of valuable elements such as buyer specific synergies, potential additional indications a series of sales-based milestone payments foreign currency and credit.
The Group has a for identified products or the premium in relation to Zomig.
centralised treasury function to manage these attributable to a well established, highly risks in accordance with Board-approved Astra Tech acquired Atlantis Components, policies.
Specifically, liquidity risk is managed regarded business in the innovative biologics market.
Such elements are instead subsumed Inc. with its specialist CAD CAM technology through maintaining access to a number within goodwill, which is not amortised.
used to design and manufacture customised of sources of funding to meet anticipated This balance between goodwill and intangible dental implant abutments, for $71 million and funding requirements, including committed Denics International Co. Ltd, its Japanese bank facilities and cash resources.
Interest assets results in an amortisation charge of approximately $435 million per annum.
Intangible assets rate risk is managed through maintaining a Further details of this acquisition are included of $121 million have been recognised with debt portfolio that is weighted towards fixed in Note 22 to the Financial Statements on associated deferred tax liability of $48 million.
Accordingly the Groups net interest charge is not significantly affected by page 130.
In October 2007, we decided, by mutual changes in floating rates of interest.
We do The other major company and product agreement, to end our collaboration with not currently hedge the impact on earnings acquisitions in 2007 reflected our NPS Pharmaceuticals, Inc. to discover and cash flow of changes in exchange rates, and develop drugs targeting metabotropic with the exception of the currency exposure ongoing commitment to strengthening the product pipeline.
We have that arises between booking and settlement agreed to pay $30 million to acquire NPSs date on non-local currency purchases and In 2007, we completed the acquisition of assets relating to the collaboration.
sales by subsidiaries and the external dividend, along with certain non-US dollar Arrow Therapeutics Limited at a net cost of $143 million, strengthening our portfolio In 2007, our recent focus on in-licensing debt.
Credit risk is managed through setting of promising anti-infective treatments and opportunities with third parties resulted in and monitoring credit limits appropriate for providing a technology platform in an area additional intangible assets on the balance the assessed risk of the counterparty.
Should any of these products fail in of research that complements our capabilities in anti-bacterials.
We paid $34 million to development, the associated intangibles acquire the paediatric asthma business of will need to be written off.
ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008 42 Our risk management objectives and policies are presented in US dollars and exposures of the long-term debt entered into in 2007 in are described in further detail below and in are managed against US dollars accordingly.
order to finance the acquisition of MedImmune, the Risk section on pages 74 to 82. has been held at fixed rates of interest.
The Approximately 57% of Group external sales Group uses interest rate swaps and forward Capital management in 2008 were denominated in currencies rate agreements to manage this mix.
The capital structure of the Group consists other than the US dollar, while a significant of shareholders equity see Note 20 on page proportion of manufacturing and R&D costs As at 31 December 2008, the Group held 129, debt see Note 14 on page 119 and were denominated in sterling and Swedish interest rate swaps with a notional value of cash see Note 13 on page 119.
Surplus cash generated by business $2.5 billion, converting the 5.4% callable bond foreseeable future, the Board will maintain units is substantially converted to, and held maturing in 2014, and the 7% guaranteed a capital structure that supports the Groups centrally, in US dollars.
As a result, operating debentures payable in 2023 to floating rates strategic objectives through: profit and total cash flow in US dollars will be and partially converting the 5.4% callable affected by movements in exchange rates.
bond maturing in 2012 and the 5.9% callable Managing funding and liquidity risk bond maturing in 2017 to floating rates.
Optimising shareholder return This currency exposure is managed centrally No new interest rate swaps were entered Maintaining a strong investment based on forecast cash flows for the into during 2008.
The majority of the Groups grade rating currencies of Swedish krona, sterling, euro, cash balances are held with third party fund Australian dollar, Canadian dollar and managers with floating rates of interest Funding and liquidity risk are reviewed Japanese yen.
The impact of movements being earned.
regularly by the Board and managed in in exchange rates is mitigated significantly accordance with policies described below.
by the correlations which exist between Sensitivity analysis considering the Groups The Boards distribution policy comprises the major currencies to which the Group is exposure to interest rate movements is both a regular cash dividend and, subject exposed and the US dollar.
Monitoring of detailed in Note 16 to the Financial Statements to business needs, a share re-purchase currency exposures and correlations is on pages 122 to 126. component.
The Board regularly reviews its undertaken on a regular basis and hedging shareholders return strategy, and for 2008 is subject to pre-execution approval.
Except Credit exposure reaffirmed the current dividend policy, which as noted below, no hedges were outstanding The Group is exposed to credit risk on is to grow dividends in line with reported at the year-end.
financial assets, such as cash balances earnings before restructuring and synergy including fixed deposits and cash and cash costs, with an aim to maintain at least two The Group will hold debt in non-US dollar equivalents, derivative instruments, trade times dividend cover.
With respect to share currencies to the extent that there is an and other receivables.
The Group is also re-purchases, the Board decided in quarter underlying net investment in the same exposed in its net asset position to its own three that no further share re-purchases credit risk in respect of the 2023 debentures currency and therefore a net investment should take place in 2008 in order to maintain hedge as defined by IFRS 7, can be applied.
and 2014 bonds which are accounted for at the flexibility to invest in the business.
For the The 500 million 2010 bond issued in 2008 fair value through profit or loss.
same reason, the Board has decided that no was issued in euros to match investors share re-purchases will take place in 2009.
During the year, the Company established a appetite but currency swaps were transacted to convert it into a US dollar instrument.
As credit risk oversight group, consisting of senior The Groups current long-term credit rating at 31 December 2008, after currency swaps, members of the Finance function to monitor is A1 by Moodys and AAby Standard and 4.2% of interest bearing loans and borrowings credit related risks and risk management Poors, both with a stable outlook.
processes, in response to the ongoing were denominated in sterling and 17.8% of interest bearing loans and borrowings were financial markets and economic uncertainty.
Liquidity risk denominated in euros.
The Board reviews the Groups ongoing Trade receivable exposures are managed liquidity risks annually as part of the planning locally in the operating units where they arise The transaction exposures that arise from process.
The Board considers short-term non-local currency sales and purchases by and credit limits are set as deemed appropriate requirements against available sources of subsidiaries are, where practicable, fully for the customer.
funding taking into account cash flow.
hedged using forward foreign exchange The Group manages liquidity risk by Exposure to financial counterparty credit risk contracts.
In addition, the Groups external maintaining access to a number of sources dividend, which is paid principally in sterling is controlled by the treasury team centrally of funding, which are sufficient to meet and Swedish krona, is fully hedged from in establishing and monitoring counterparty anticipated funding requirements.
Specifically, announcement to payment date.
limits, which are set according to the assessed the Group uses US commercial paper, risk of each counterparty.
Centrally managed committed bank facilities and cash resources Sensitivity analysis considering the Groups funds are invested entirely with counterparties to manage short-term liquidity and manages exposure to exchange rate movements is whose credit rating is A or better.
During the long-term liquidity by raising funds through detailed in Note 16 to the Financial Statements year, funds held in money market funds have the capital markets.
Facilities available to the been progressively transferred to US Treasury on pages 122 to 126.
Group are detailed in Note 15 to the Financial funds, in light of the ongoing financial crisis.
Interest rate risk The Group maintains a mix of fixed and floating External fund managers, who manage Foreign exchange $3.0 billion of the Groups cash, are rated rate debt.
The portion of fixed rate debt was The US dollar is the Groups most significant approved by the Board and any variation AAA by Standard & Poors.
As a consequence, the Group results requires Board approval.
A significant portion ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008 DIREcTORs REPORT 43 CRITICAl ACCouNTINg polICIES customer depending on local trading terms.
The effects of these deductions on our US ANd ESTImATES Income from royalties and from disposals of pharmaceuticals turnover are set out below.
intellectual property, brands and product lines Our Financial Statements are prepared in are included in other operating income.
Accrual assumptions are built up on a accordance with International Accounting product-by-product and customer-byStandards and International Financial Reporting Rebates and chargebacks customer basis taking into account specific Standards collectively IFRSs as adopted At the time of invoicing sales in the US, rebates contract provisions coupled with expected by the European Union adopted IFRS and and chargebacks that we expect to pay, in as performance and are then aggregated into as issued by the International Accounting little time as two weeks or as much as eight a weighted average rebate accrual rate for Standards Board and the accounting policies months, are estimated.
These rebates typically each of our products.
Accrual rates are employed are set out under the heading arise from sales contracts with third party reviewed and adjusted on a monthly basis.
Financial Statements Accounting Policies on managed care organisations, hospitals, There may be further adjustments when pages 103 to 107.
In applying these policies, long-term care facilities, group purchasing actual rebates are invoiced based on we make estimates and assumptions that organisations and various federal or state utilisation information submitted to us in affect the reported amounts of assets and programmes Medicaid best price contracts, the case of contractual rebates and claims liabilities and disclosure of contingent assets supplemental rebates etc and can be invoices are received in the case of regulatory and liabilities.
The actual outcome could differ classified as follows: rebates and chargebacks.
We believe that from those estimates.
Some of these policies we have been reasonable in our estimates for require a high level of judgement, either Chargebacks, where we enter into future rebates using a similar methodology to because the areas are especially subjective arrangements under which certain parties, that of previous years.
Inevitably, however, such or complex.
We believe that the most critical typically hospitals, the Department of estimates involve judgements on aggregate accounting policies and significant areas of Veterans Affairs and the Department of future sales levels, segment mix and the judgement and estimation are in: Defense, are able to buy products from respective customer contractual performance.
wholesalers at the lower prices we have Revenue recognition contracted with them.
The chargeback Cash discounts are offered to customers to Research and development is the difference between the price encourage prompt payment.
Accruals are Goodwill and intangible assets we invoice to the wholesaler and calculated based on historical experience Litigation the contracted price charged by the and are adjusted to reflect actual experience.
Chargebacks are paid Taxation directly to the wholesalers.
Industry practice in the US allows Share-based compensation.
wholesalers and pharmacies to return Regulatory, including Medicaid and other unused stocks within six months of, and up REVENuE RECogNITIoN federal and state programmes, where we to 12 months after, shelf-life expiry.
At point Revenue is recorded at the invoiced amount pay rebates based on the specific terms of sale, we estimate the quantity and value excluding inter-company sales and value of agreements in individual states which of goods which may ultimately be returned.
added taxes less movements in estimated include product usage and information Our returns accruals are based on actual accruals for product returns and rebates on best prices and average market experience over the preceding 12 months given to managed care and other customers prices benchmarks.
for established products together with a particular feature in the US but also market related information such as occurring in the rest of the world.
Cash Contractual, under which entities such as estimated stock levels at wholesalers and discounts for prompt payment are also third party managed care organisations, competitor activity.
For newly launched deducted from sales.
Revenue is recognised long-term care facilities and group products, we use rates based on our at the point of delivery, which is usually when purchasing organisations are entitled experience with similar products or a title passes to the customer either on to rebates depending on specified pre-determined percentage.
shipment or on receipt of goods by the performance provisions, which vary from contract to contract.
2008 2007 2006 $m $m $m Gross sales 20,029 18,456 16,577 Chargebacks 1,726 1,130 975 Regulatory US government and state programmes 1,005 732 532 Contractual Managed care and group purchasing organisation rebates 3,658 3,179 2,413 Cash and other discounts 390 356 329 Customer returns 48 18 46 Other 167 145 256 Net sales 13,035 12,896 12,026 ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008 44 For products facing generic competition vary from product to product depending The increase in contractual rebates in 2007 such as Ethyol and Toprol-XL in the US our on the specific circumstances.
was driven by the introduction into the US experience is that we usually lose the ability market of generic omeprazole, with resultant to estimate the levels of returns from The movements on US pharmaceuticals price impacts on Nexium.
wholesalers with the same degree of revenue accruals, are set out below.
precision that we can for products still We have Distribution Service Agreements with subject to patent protection.
This is because The adjustments in respect of prior years major wholesaler buyers, which serve to we have limited or no insight into a number benefited reported US pharmaceuticals reduce the speculative purchasing behaviour of areas the actual timing of the launch of turnover by 0.4% in 2006, and decreased of the wholesalers and reduce short-term a generic competitor following regulatory turnover by 0.4% in 2007 and 0.2% in 2008. fluctuations in the level of inventory they hold.
approval of the generic product for As a result, we believe inventory movements example, a generic manufacturer may or Chargebacks increased by $173 million have been neutral across the year.
We track may not have produced adequate precompared to 2007 due primarily to increased wholesaler stock levels by product, using our launch inventory, the pricing and marketing sales activities with US Government Agencies own, third party and wholesaler data and, strategy of the competitor, the take-up of the for Nexium and Crestor.
Regulatory rebates where we believe such distortions occur, generic and in cases where a generic increased by $92 million in 2008 largely as we disclose in the Annual Report for each manufacturer has approval to launch just one a result of increased US State supplemental product and in aggregate where shipments dose size in a market of several dose sizes rebates for our key brands.
In 2008 contractual may be out of line with underlying prescription the likely level of switching from one dose to rebates increased by $184 million compared trends.
We do not offer any incentives to another.
Under our accounting policy revenue to 2007, mainly as a result of AstraZenecas encourage wholesaler speculative buying is only recognised when the amount of the response to increased generic and competitor and attempt, where possible, to restrict revenue can be measured reliably.
Our pricing pressures particularly in the PPI and shipments to underlying demand when approach in meeting this condition for statin markets.
products facing generic competition will Adjustment Carried forward Brought forward Provision for in respect Returns at 31 December 1 January 2006 current year of prior years and payments 2006 $m $m $m $m $m Chargebacks 185 1,001 26 1,068 92 Regulatory US government and state programmes 601 597 65 819 314 Contractual Managed care and group purchasing organisation rebates 420 2,367 46 2,198 635 Cash and other discounts 27 329 327 29 Customer returns 167 46 53 160 Other 54 256 263 47 1,454 4,596 45 4,728 1,277 Additions in Adjustment Carried forward Brought forward respect of Provision for in respect Returns at 31 December 1 January 2007 MedImmune current year of prior years and payments 2007 $m $m $m $m $m $m Chargebacks 92 2 1,115 15 1,038 186 Regulatory US government and state programmes 314 69 769 37 687 428 Contractual Managed care and group purchasing organisation rebates 635 5 3,100 79 2,919 900 Cash and other discounts 29 1 356 348 38 Customer returns 160 1 19 1 94 85 Other 47 153 147 53 1,277 78 5,512 56 5,233 1,690 Adjustment Carried forward Brought forward Provision for in respect Returns at 31 December 1 January 2008 current year of prior years and payments 2008 $m $m $m $m $m Chargebacks 186 1,745 19 1,553 359 Regulatory US government and state programmes 428 997 8 913 520 Contractual Managed care and group purchasing organisation rebates 900 3,622 36 3,474 1,084 Cash and other discounts 38 390 389 39 Customer returns 85 48 56 77 Other 53 167 163 57 1,690 6,969 25 6,548 2,136 ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008 DIREcTORs REPORT 45 of the intangible asset.
This is because the discount rate reflecting those risks and tax Royalty income Royalty income is recorded under other contracted revenue relating to the undelivered effects.
In arriving at the appropriate discount operating income in the Financial Statements.
component is contingent on future events rate for each group of cash flows, we adjust Royalties tend to be linked to levels of sales such as sales and so cannot be anticipated.
AstraZenecas post-tax weighted average cost of capital 7.6% for 2008 to reflect the or production by a third party.
At the time of preparing the Financial Statements, we may RESEARCh ANd dEVElopmENT impact of risks and tax effects.
The weighted have to estimate the third partys sales or Our business is underpinned by our marketed average pre-tax discount rate we used was production when arriving at the royalty products and development portfolio.
expenditure on internal activities to generate income to be included.
These estimates, which may differ from actual sales or these products is generally charged to the As a cross check, we compare our market production, do not result in a material impact income statement in the year that it is incurred.
capitalisation to the book value of our net on reported other operating income.
Purchases of intellectual property and product assets and this indicates significant surplus rights to supplement our R&D portfolio are at 31 December 2008.
Sales of intangible assets capitalised as intangible assets.
Such intangible A consequence of charging all internal R&D assets are amortised from the launch of the No goodwill impairment was identified.
expenditure to the income statement in the underlying products and are tested for impairment both before and after launch.
The Group has also performed sensitivity year that it is incurred which is normal practice in the pharmaceutical industry is This policy is in line with practice adopted by analysis calculations on the projections used that we own valuable intangible assets which major pharmaceutical companies.
The Directors are not recorded on the balance sheet.
have concluded that, given the significant goodWIll ANd INTANgIBlE ASSETS headroom that exists, and the results of the We also own acquired intangible assets which are included on the balance sheet.
We have significant investments in goodwill sensitivity analysis performed, there is no As a consequence of regular reviews of and intangible assets as a result of acquisitions significant risk that reasonable changes in product strategy, from time to time we sell of businesses and purchases of such assets key assumptions would cause the carrying as product development and marketing rights.
value of goodwill to exceed its value in use.
such assets and generate income.
Sales of product lines are often accompanied by an agreement on our part to continue For the purpose of impairment testing of Impairment reviews have been carried out manufacturing the relevant product for a goodwill, the Group is regarded as a single on all intangibles that are in development cash-generating unit.
and not being amortised, all major intangibles reasonable period often about two years whilst the purchaser constructs its own acquired during the year, all intangibles that manufacturing facilities.
The contracts typically The recoverable amount is based on value in have had indications of impairment during involve the receipt of an upfront payment, use using discounted risk-adjusted projections the year and all intangibles recognised on the acquisition of MedImmune.
Sales forecasts which the contract attributes to the sale of of the Groups pre-tax cash flows over ten the intangible assets, and ongoing receipts, years, a period reflecting the average and specific allocated costs which have which the contract attributes to the sale of patent-protected lives of our current products.
both been subject to appropriate Senior the product we manufacture.
In cases where The projections include assumptions about Management sign off are discounted using AstraZenecas post-tax weighted average the transaction has two or more components, product launches, competition from rival we account for the delivered item for example, products and pricing policy as well as the cost of capital.
the transfer of title to the intangible asset as possibility of generics entering the market.
a separate unit of accounting and record In setting these assumptions we consider The majority of our investments in intangible assets and goodwill arose from the revenue on delivery of that component our past experience, external sources of provided that we can make a reasonable information including information on expected restructuring of the Astra-Merck joint venture estimate of the fair value of the undelivered increases and ageing of the populations in in 1998, the acquisition of MedImmune in component.
Where the fair market value of our Established Markets and the expanding 2007 and the payment to partially retire Mercks interests in our products in the US in the undelivered component for example patient population in newer markets, a manufacturing agreement exceeds the our knowledge of competitor activity and 2008, and we are satisfied that the carrying contracted price for that component we our assessment of future changes in the values are fully justified by estimated future defer an appropriate element of the upfront pharmaceutical industry.
The 10 year period cash flows.
consideration and amortise this over the is covered by internal budgets and forecasts.
However, where the fair Given that internal budgets and forecasts lITIgATIoN market value of the undelivered component are prepared for all projections, no general In the normal course of business, potential is equal to or lower than the contracted price growth rates are used to extrapolate internal liabilities may arise from product-specific and general legal proceedings, from guarantees for that component we treat the whole of the budgets and forecasts for the purposes of upfront amount as being attributable to the determining value in use.
or from environmental liabilities connected delivered intangible assets and recognise that with our current or former sites.
Where we part of the revenue upon delivery.
No element In arriving at value in use, we disaggregate believe that potential liabilities have a less than 50% probability of crystallising or are of the contracted revenue related to the our projected pre-tax cash flows into groups undelivered component is allocated to the sale reflecting similar risks and tax effects.
For each very difficult to quantify reliably, we treat them group of cash flows we use an appropriate as contingent liabilities.
ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008 46 results in a broad diversification of investment Included in the total net accrual are These are not provided for but are disclosed in the Notes to the Financial Statements.
The investment amounts in respect of the following transfer Further details of these contingent liabilities approach is intended to produce less volatility pricing arrangements: are set out in Note 25 on page 144.
Where in the plan asset returns.
AstraZeneca and Her Majestys Revenue it is considered more likely than not that an actual liability may crystallise, and this can In assessing the discount rate applied to & Customs HMRC have made a joint be measured reliably, a provision is made.
the obligations, we have used rates on AA referral to the UK Court in respect of Although there can be no assurance regarding corporate bonds with durations corresponding transfer pricing between our UK and one to the maturities of those obligations.
of our overseas operations for the years the outcome of legal proceedings, we do not currently expect them to have a materially 1996 to date as there continues to be a adverse effect on our results in any particular In all cases, the pension costs recorded material difference between the Groups period.
We also have significant commitments in the Financial Statements are assessed in and HMRCs positions.
An additional accordance with the advice of independent referral in respect of controlled foreign that are not currently recognised in the balance sheet arising from our relationship with Merck.
qualified actuaries but require the exercise of company aspects of the same case was These are described more fully in Note 25 to significant judgement in relation to assumptions made during 2008.
Absent a negotiated the Financial Statements on page 144. for future salary and pension increases, longsettlement, litigation is set to commence term price inflation and investment returns.
in 2010. poST-RETIREmENT BENEFITS We offer post-retirement benefit plans which TAxATIoN AstraZeneca has applied for two advance cover many of our employees around the Accruals for tax contingencies require pricing agreements APAs in relation to management to make judgements and intra-group transactions between the UK world.
In keeping with local terms and conditions, most of these plans are defined estimates in relation to tax audit issues and and the US and the UK and Japan.
Both contribution in nature where the resulting exposures.
Amounts accrued are based on APAs are being progressed through income statement charge is fixed at a set managements interpretation of country-specific competent authority proceedings under tax law and the likelihood of settlement.
Tax the relevant double tax treaties.
level or is a set percentage of employees pay.
However, several plans, mainly in the benefits are not recognised unless the tax UK which has by far the largest single positions are probable of being sustained.
Management continues to believe that scheme, the US and Sweden, are defined Once considered to be probable, management AstraZenecas positions on all its transfer reviews each material tax benefit to assess pricing audits and disputes are robust and benefit plans where benefits are based on employees length of service and final salary whether a provision should be taken against that AstraZeneca is adequately provided.
typically averaged over one, three or five full recognition of the benefit on the basis of years.
The UK and US defined benefit potential settlement through negotiation and For transfer pricing audits where AstraZeneca and the tax authorities are in dispute, schemes were closed to new entrants in or litigation.
All such provisions are included 2000.
All new employees in these countries in creditors due within one year.
Any recorded AstraZeneca estimates the potential for are offered defined contribution schemes.
exposure to interest on tax liabilities is provided reasonably possible additional losses above for in the tax charge.
and beyond the amount provided to be up to $400 million: however, management In applying IAS 19 Employee Benefits, we recognise all actuarial gains and AstraZeneca faces a number of transfer pricing believes that it is unlikely that these additional losses immediately through reserves.
This audits in jurisdictions around the world and, losses will arise.
Of the remaining tax methodology results in a less volatile income in some cases, is in dispute with the tax exposures, AstraZeneca does not expect material additional losses.
It is not possible statement charge than under the alternative authorities.
These disputes usually result in approach of recognising actuarial gains taxable profits being increased in one territory to estimate the timing of tax cash flows in and losses over time.
Investment decisions and correspondingly decreased in another.
relation to each outcome, however, it is in respect of defined benefit schemes are Our balance sheet positions for these matters anticipated that a number of significant disputes may be resolved over the next based on underlying actuarial and economic reflect appropriate corresponding relief in circumstances with the intention of ensuring the territories affected.
The total net accrual one to two years.
Included in the provision that the schemes have sufficient assets to included in the Financial Statements to cover is an amount of interest of $365 million.
meet liabilities as they fall due, rather than the worldwide exposure to transfer pricing meeting accounting requirements.
The trustees audits is $1,628 million, an increase of follow a strategy of awarding mandates to $306 million due to a number of new audits, specialist, active investment managers which revisions of estimates relating to existing audits, offset by a number of negotiated settlements and exchange rate effects.
ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008 DIREcTORs REPORT 47 pAYmENTS duE BY pERIod Less than 1 year 1-3 years 3-5 years Over 5 years Total $m $m $m $m $m Bank loans and other borrowings 1,616 2,800 2,665 12,478 19,559 Operating leases 101 131 81 145 458 Contracted capital expenditure 332 332 Total 2,049 2,931 2,746 12,623 20,349 ShARE-BASEd CompENSATIoN Our approach to the assessment has been to Through the Remuneration Committee we select key transaction and financial reporting offer share and share option plans to certain processes in our largest operating units and employees as part of their compensation a number of specialist areas such as financial and benefits packages, designed to improve consolidation and reporting, treasury alignment of the interests of employees operations and taxation so that, in aggregate, with shareholders.
Costs of the plans are we have covered a significant proportion of determined using valuation models such as each of the key line items in our Financial Black-Scholes or a modified version of the Statements.
Each of these operating units binomial model.
Valuation models require and specialist areas has ensured that its judgements to be made on inputs to the relevant processes and controls are model.
Further details of these are given documented to appropriate standards, in Note 24 to the Financial Statements.
taking into account, in particular, the guidance provided by the Securities and oFF-BAlANCE ShEET TRANSACTIoNS Exchange Commission.
We have also ANd CommITmENTS reviewed the structure and operation of our We have no off-balance sheet arrangements entity level control environment.
This refers and our derivative activities are non-speculative.
to the overarching control environment, The table above sets out our minimum including structure of reviews, checks contractual obligations at the year end.
and balances that are essential to the management of a well controlled business.
oThER ACCouNTINg INFoRmATIoN The Directors have concluded that our internal INTERNATIoNAl ACCouNTINg TRANSITIoN control over financial reporting is effective as On transition to using adopted IFRS in the at 31 December 2008 and the assessment year ended 31 December 2005, we took is set out on page 98.
KPMG Audit Plc have advantage of several optional exemptions audited the effectiveness of internal control available in IFRS 1 First-time Adoption of over financial reporting and, as noted on International Financial Reporting Standards.
page 99, their report is unqualified.
The major effects of these exemptions are detailed on page 106.
NEW ACCouNTINg STANdARdS New International Financial Reporting Standards which have been issued both adopted and not yet adopted are discussed on pages 103 to 107.
SARBANES-oxlEY ACT SECTIoN 404 As a consequence of our listing on the New York Stock Exchange, AstraZeneca is required to comply with those provisions of the US Sarbanes-Oxley Act applicable to foreign issuers.
Section 404 of this legislation requires companies annually to assess and make public statements about the quality and effectiveness of their internal control over financial reporting.
ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008
